Approved TherapeuticAugust 5, 2026
Semaglutide
Ozempic
Type 2 diabetes · Chronic weight management
Tier 1Approved
SafetyKnown but Manageable Risks
- Sponsor
- Novo Nordisk
- Phase
- Approved
Loading Daily Peptide Guide…
Product-specific approvals with evidence and safety shown independently.
Ozempic
Type 2 diabetes · Chronic weight management
Mounjaro
Type 2 diabetes · Chronic weight management
Victoza
Type 2 diabetes · Chronic weight management
Trulicity
Type 2 diabetes · Cardiovascular risk reduction
Forteo
Osteoporosis · High fracture risk
Tymlos
Osteoporosis · High fracture risk
Sandostatin
Acromegaly · Carcinoid syndrome
Somatuline Depot
Acromegaly · Neuroendocrine tumors
Leuprorelin
Prostate cancer · Endometriosis
Gattex
Short bowel syndrome
Linzess
Irritable bowel syndrome with constipation · Chronic idiopathic constipation
Trulance
Chronic idiopathic constipation · IBS-C
Prialt
Severe chronic pain
Recombinant human growth hormone
Growth-hormone deficiency · Selected growth disorders
Increlex
Severe primary IGF-1 deficiency
Egrifta
Excess abdominal fat in adults with HIV-associated lipodystrophy
Lutathera
Gastroenteropancreatic neuroendocrine tumors · Theranostics
SS-31
Barth syndrome · Mitochondrial disease research